6-Fluoromevalonate blocks the incorporation of mevalonic acid, but not that of isopentenyl pyrophosphate, into non-saponifiable lipids in a rat liver multienzyme system. With 3H-labelled 6-fluoromevalonate, it was found that 6-fluoromevalonate is converted to its phospho and pyrophospho derivatives in this system. The kinetics of the two kinases were studied. 6-Fluoromevalonate 5-pyrophosphate is a potent competitive inhibitor of pyrophosphomevalonate decarboxylase (Ki 37nM). In the multienzyme assay for cholesterol biosynthesis, there is accumulation of mevalonate 5-phosphate and mevalonate 5-pyrophosphate in the presence of 5pM-6-fluoromevalonate, and 6-fluoromevalonate 5-pyrophosphate is more effective than 6-fluoromevalonate in inhibiting cholesterol biosynthesis. We suggest therefore that 6-fluoromevalonate blocks cholesterol biosynthesis at the level of pyrophosphomevalonate decarboxylase after being pyrophosphorylated.
6-Fluoromevalonate blocks the incorporation of mevalonic acid, but not that of isopentenyl pyrophosphate, into non-saponifiable lipids in a rat liver multienzyme system. With 3H-labelled 6-fluoromevalonate, it was found that 6-fluoromevalonate is converted to its phospho and pyrophospho derivatives in this system. The kinetics of the two kinases were studied. 6-Fluoromevalonate 5-pyrophosphate is a potent competitive inhibitor of pyrophosphomevalonate decarboxylase (Ki 37nM). In the multienzyme assay for cholesterol biosynthesis, there is accumulation of mevalonate 5-phosphate and mevalonate 5-pyrophosphate in the presence of 5pM-6-fluoromevalonate, and 6-fluoromevalonate 5-pyrophosphate is more effective than 6-fluoromevalonate in inhibiting cholesterol biosynthesis. We suggest therefore that 6-fluoromevalonate blocks cholesterol biosynthesis at the level of pyrophosphomevalonate decarboxylase after being pyrophosphorylated.
Hypercholesterolaemia is considered to be a major risk factor in coronary artery diseases (Kolata, 1983) . This correlation, if not causal rerationship, explains the constant efforts made to understand the regulation and to find inhibitors of cholesterol biosynthesis. With few exceptions (Hulcher, 197 1; Shama Bhat & Ramasarma, 1979; Rowan Debold & Elwood, 1981; Miller et al., 1981) the main emphasis has been put on the ratelimiting enzyme, hydroxymethylglutaryl-CoA reductase (EC 1.1.1.34). The reports that 6-FMVA decreases the conversion of acetate and mevalonate into cholesterol in perfused rat liver (Brauser & Hermann, 1965) and also blocks the synthesis of juvenile hormone in insect larvae (Quistad et al., 1981a) led us to investigate its mode of action. We report here that 6-FMVA is converted to its FMVAPP is a strong competitive inhibitor of MVAPP decarboxylase. (Cornforth & Popj'ak, 1969) . All other reagents were of analytical grade.
Synthesis of 6-fluoro[5-3 H]mevalonolactone
Fluoromethyl diallyl carbinol was synthesized as described by Quistad et al. (198 lb) . This synthesis of 6-FMVA was modified as follows.
Ozone was bubbled into a solution of 2.Og of fluoromethyl diallyl carbinol dissolved in 80ml of methylene dichloride and 4ml of methanol at -78°C until persistence of the blue colour. After elimination of the excess ozone with a stream of N2
Vol. 227 14ml of dimethyl sulphide was added and the mixture was stirred for 1 h at -40C, 1 h at -20°C, and overnight at 0°C. After evaporation to dryness, the oily residue was chromatographed on silica to yield 1.4g of a mixture showing two spots on t.l.c. and no aldehydic protons by n.m.r. A solution of 440mg of this mixture in 10ml of methylene dichloride was allowed to react with 41 mg of NaB3H4 (lOOmCi) dissolved in 2.2ml of 2-methoxyethyl ether for 2h at 40-60°C. After addition of 49mg of unlabelled NaBH4, the reaction mixture was stirred overnight at room temperature and quenched with 1 ml of acetic acid. Solvent evaporation and chromatography on silica gel yielded 274mg of radiolabelled 3-fluoromethylpentane-1,3,5-triol (sp. radioactivity 10.4mCi/ mmol).
A solution of 274mg of triol in 16ml of acetone was treated at 0°C with 1.2ml of Jones' reagent (2.67 M-CrO3 in 8 M-H2 S04) added dropwise. After 3 h at room temperature the reaction was quenched by a few drops of propan-2-ol, diluted with 30ml of water, concentrated under reduced pressure and the lactone was extracted with warm methylene dichloride. After drying, evaporation and silica gel chromatography, 128 mg of pure labelled 6-FMVA were obtained (sp. radioactivity 6.8 mCi/mmol Quistad et al. (1981b) .
Rat liver multienzyme system Preparation of rat liver (Sprague-Dawley rats) 100OOg supernatant as well as cholesterol biosynthesis were conducted according to Raulston et al. (1980) . The substrates used were either radiolabelled MVA or IPP.
For the measurement of squalene and sterol formation, the reaction mixture was saponified and extracted with light petroleum as described by Popjak (1969) . Total radioactivity incorporated into the nonsaponifiable extract was measured.
For the determination of water-soluble precursors of cholesterol, the incubation mixture was heated for 3min in boiling water. After centrifugation, aliquots of the supernatant were analysed by t.l.c. with propan-l-ol/NH40H/water (6:3:1, by vol.). Radioactive spots were located with a t.l.c. radioactivity scanner (Berthold model LB 2723). Spots were scraped off and transferred into counting vials for measure of radioactivity in a scintillation cocktail consisting of 6g of 2,5-diphenyloxazole 0.2g of 1,4-bis-(4-methyl-5-phenyloxazol-2-yl)benzene in 1 litre of toluene/methanol (8: 1, v/v).
Mevalonate kinase
The enzyme was partially purified from pig liver according to Popjak, (1969) (Popjak, 1969) which couples the pyruvate kinase/lactate dehydrogenase system to mevalonate kinase was used with minor modifications. All measurements were performed at 25°C with a double beam recording difference spectrophotometer. Each cuvette contained 0.4mM-NADH, 6.5 rM-ATP, 0.85 mM-phosphoenolpyruvate, SmM-MgCI2, 10mM-cysteine (freshly liberated from its hydrochloride with KOH), 0.1 MTris/HCl, pH7.3, 12units of lactate dehydrogenase/ml, 23 units of pyruvate kinase/ml and the enzyme in a total assay volume of 1.2ml. The reaction was started by addition of substrate in 40pl to the reference cell. The same volume of water was added to the assay cell. Absorbance difference was measured at 340nm. The initial velocities were determined from the slope of the recorder tracing. The ability of the pyruvate kinase/lactate dehydrogenase system to oxidize NADH in a rapid and quantitative way following ADP addition was checked before each series of experiments.
Phosphomevalonate kinase
The pig liver enzyme was purifed following the method of Bazaes et al. (1980) up to the DEAE-cellulose step (0.15 unit/mg of protein). This enzyme, free of pyrophosphomevalonate decarboxylase, was used for the kinetic experiments. It was stored in 10mM-phosphate buffer, pH7.5, containing 1 mM-2-mercaptoethanol at -20°C and kept well for many months. The enzyme was assayed at pH 7.6 using the same spectrophotometric assay as for mevalonate kinase except that ATP concentration was 3.3mM, and the substrate was MVAP.
Pyrophosphomevalonate decarboxylase
Purification of the chicken liver enzyme was carried out according to Alvear et al. (1982) . After the Sephadex G-200 step, the enzyme (0.11 unit/mg of protein) was kept at -20°C in 4mM-phosphate buffer, pH 7.0, containing 8 mM-2-mercaptoethanol, 0.08mM-EDTA and 20% (v/v) glycerol and remained stable for at least 2 months. The radioactive assay according to Alvear et al. (1982) was used throughout the enzyme purification.
Commercial (R)-[2-1 4C]MVAPP (55 mCi/mmol) diluted with biosynthesized (R)-MVAPP was used as substrate. For the kinetic experiments, a spectrophotometric assay coupling pyruvate kinase and lactate dehydrogenase to MVAPP decarboxylase (Alvear et al., 1982) was used. Assays were performed at 30°C and pH 7.0. One enzyme unit is defined as the amount of enzyme decarboxylating MVAPP at an initial rate of 1 4umol/min at 30°C under the assay conditions.
Preparation of MVAP and MVAPP
The large scale preparation of MVA kinase was used to prepare at the same time MVAP and
with 120units of enzyme preparation under the conditions described by Popjak (1969) -for 1.5h. After protein precipitation by heating at 80°C for 3min, centrifugation and extraction in 80% ethanol at pH 7.4, the reaction products were separated by ion-exchange chromatography on a DEAESephadex A-25 column (60cm x 2.6cm). After washing with 1.1 litre of water the MVAP and MVAPP were eluted by a linear gradient of (NH4)2CO3 (2 litres, 0-0.35M). MVAPP was contaminated with MVAP and needed an additional purification on a smaller column of the same resin. (NH4)2CO3 was eliminated by lyophilization. The yields were 341 mg of (R)-MVAP and 60mg of (R)-MVAPP. The compounds were homogenous on t.l.c. (silica gel 60; propan-l-ol/NH40H/water, 6:3 :1 by vol.) when revealed either by a spray of reagent specific for phosphorus-containing compounds or by scanning for radioactivity.
[ Miscellaneous methods MVA and 6-FMVA were prepared as their potassium salts in solutions at pH 7.5 from the respective lactones according to Popj'ak (1969) . Stock solutions of the phosphorus derivatives of MVA and 6-FMVA were prepared in water and stored at -20°C. Their phosphorus content was determined according to Rouser et al. (1970) . Protein determinations were made according to the method of Lowry et al. (1951) . The solvent mixture used for separation on t.l.c. of MVA, 6-FMVA and their products of enzymic conversion was always propan-l-ol/NH3/water (6:3:1, by vol.) and is referred to as the standard t.l.c. system.
Results
Localization of the site of cholesterol biosynthesis inhibition by 6-FMVA The 100OOg supernatant of a rat liver homogenate contains all the enzymes needed to synthesize cholesterol from mevalonate (Popjak et al., 1978; Raulston et al., 1980) or from I PP. As can be seen in Table 1 , the incorporation of radioactivity supernatant from rat liver supplemented with cofactors according to Raulston et al. (1980) in a final assay volume of Iml with or without 6-FMVA. Incubation was stopped with 2ml of 4M ethanolic KOH solution. After saponification for 2 h at 70°C, the non-saponifiable lipids were extracted twice with 3 ml of light petroleum and total radioactivity was determined in this extract. Vol. 227
into non-saponifiable lipids is rapid during the first 10min and is not linear with long times of incubation. Addition of 5JMu-6-FMVA blocks extensively the incorporation of mevalonate into non-saponifiable lipids at the 10min time point (93%); the effect diminishes with the incubation time (52% at 50min). When IPP-is used as precursor of sterols, 6-FMVA no longer has an effect either at short or at long time points.
In the second part of this experiment, the distribution of radioactivity among the watersoluble metabolites of MVA was determined in the absence or presence of 6-FMVA. As can be seen in Fig. 1 , the elution profiles are totally different. All peaks except 3 could be identified by spiking with authentic samples: a is MVAPP, fi is IPP, y is MVAP; 3 could possibly be farnesyl -pyrophosphate. While MVAP and MVAPP are not found in control incubations, they represent the main radioactive products in presence of 6-FMVA. On the contrary, IPP and peak 3 are absent from the experiment with the inhibitor.
Formation and characterization of phosphorylated metabolites of 6-FM VA Radiolabelled 6-FMVA was incubated with the rat liver multienzyme system under similar conditions as for mevalonate. The reaction was followed by t.l.c. Fig. 2 shows a radiochromatogram obtained after 2.5 h of incubation. Besides unchanged 6-FMVA, three major radioactive products A, B and C can be detected: they represent 3, 15 and 2.5% of total applied radioactivity respectively. Biosynthesis of these metabolites for preparative purposes was attempted under the conditions described for MVAP and MVAPP biosynthesis above. Partially purified mevalonate kinase (60 units), which also contains phosphomevalonate kinase, were incubated with 1.5mmol of (R,S)-6-FMVA containing 350/uCi of the 3H-labelled compound at 30°C for 7 h. The formation of metabolites of 6-FMVA was followed by t.l.c. in the standard system. Assuming that only (R)-6-FFMVA was transformed, a maximum of 65% conversion was reached after about 4h. Separation and recovery of the individual metabolites was achieved as for the phosphorylated metabdlitesof MVA. Five peaks were collected, as shown in Fig.  3 . Peak I (RF 0.6) in the standard t.l.c. system corresponded.to unreacted 6-FMVA.. Peak II contained no fluorine ('9F-n.m.r.) and was discarded.
Peaks III and IV needed a second DEAESephadex column for complete separation. Peak V was contaminated with nucleotides and was purified by t.l.c. followed by a second DEAESephadex column. Compounds IV and V were homogenous on t. Comparison -of 6-FMVA and 6-FMVAPP as inhibitors of cholesterol biosynthesis The inhibition of cholesterol biosynthesis in the multienzyme system by 6-FMVA and 6-FMVAPP was studied as a function of time (Fig. 4) . The two compounds were added at a concentration of 5uM. It clearly appears that 6-FMVAPP is a stronger inhibitor of cholesterol biosynthesis than 6-FMVA. The inhibition is almost total at the 10min incubation point and seems to be relieved at longer time points. This could possibly be due to the Vol. 227 hydrolytic action of phosphatases on 6-FMVA PP, although this was not verified.
Discussion
In the multienzyme system of rat liver, 6-FMVA inhibits the incorporation of MVA into the nonsaponifiable lipids but not that of IPP, and produces accumulation of MVAPP and to a lesser extent of MVAP. This clearly designates the decarboxylation of MVAPP as the main target for inhibition. Indeed 6-FMVA undergoes phosphorylation and pyrophosphorylation in this system or by the partially purified kinases.
In addition to the two normal phosphate ester derivatives, a cyclic ester is formed and even represents the major metabolite. The mechanism of formation of this metabolite is not explained; we were unable to demonstrate its formation from either 6-FMVAP or 6-FMVAPP under the conditions of experimentation. This cyclic compound has only a marginal effect on the kinases or the decarboxylase (results not shown). During the decarboxylation step of MVAPP, the hydroxy on C-3 is lost and is involved in ATP hydrolysis. Substitution by the electroattractive F renders the C-O 1985 Table 2 . Kinetic parameters lor substrates and inhibitors of MVA kinase, MVAP kinase and MVAPP decarboxylase (a) The data refer to measurements at 25°C in buffer at pH7.3 and 6.5 mM-ATP for MVA kinase and in buffer at pH 7.6 and 3.3 mM-ATP for MVAP kinase. The enzymic assays were performed as described in the Experimental procedures section. The data given for each enzyme are obtained from a single experiment. (b) The data presented were obtained at 30°C by using the spectrophotometric assay according to Alvear et al. (1982 bond more resistant to cleavage; therefore, 6-FMVAPP is not a substrate of MVAPP decarboxylase but a strong competitive inhibitor. The gain in affinity of almost two log units compared with MVAPP hints towards a structure of a transition state analogue. If this hypothesis can be accepted, it would mean that during the binding process of MVAPP to the decarboxylase, the C-O bond is elongated to a point where it is broken. The fluorine substitution could prevent a positive charge at C-3 from developing in the transition state; thus during binding the breaking point would not be reached. 6-FMVAPP is the most potent inhibitor of the avian liver MVAPP decarboxylase known. p-Coumaric and isoferulic acids, described by Shama Bhat & Ramasarma (1979), have Ki values in the millimolar range.
As stated earlier on, MVAPP decarboxylase is probably the main site of blockade of cholesterol synthesis by 6-FMVA, as seen from the accumulation of MVAPP. However MVAP is also accumulated to some extent; therefore competition of 6-FMVA with MVA for MVA kinase and of 6-FMVAP with MVAP for MVAP kinase also contributes to the delay of conversion. Such an effect has been described for 3,5-dihydroxy-3,4,4-trimethylvaleric acid, a substrate of yeast MVA and MVAP kinases (Hulcher, 1982) . Introduction of the two lipophilic methyl groups on C-4 of mevalonate increases the affinity by a factor of 2 for yeast MVA kinase and by a factor of 10 for MVAP kinase; the Vmax. values have not been reported. For the mammalian enzymes, the substitution of a hydrogen atom by fluorine on C-6 does not affect Vmax.; however, the binding constants are decreased, suggesting that the electronic factor may play a role in binding. As already mentioned, 6-FMVA inhibits juvenile hormone synthesis in insects; the 6,6-difluoromevalonate however is markedly less active. If the inhibition of juvenile hormone synthesis by 6-FMVA is also mediated through the phosphorylated metabolites, due to the effect of the fluorine atom on the binding constants to the kinases, it is likely that the difluoro analogue is poorly phosphorylated. It would be interesting to synthesize chemically the pyrophosphorylated analogue of 6,6-difluoromevalonate and to study its interaction with MVAPP decarboxylase. Quistad et al. (1981a) concluded that 6-FMVA is not potent enough to be of practical utility as an insecticide. This statement is probably also valid for the control of cholesterol biosynthesis in mammals. Even though the pyrophosphorylated derivative is a powerful inhibitor of MVAPP decarboxylase, the conversion of 6-FMVA is too slow and not complete. In addition, part of the compound is diverted to the cyclic phosphate ester for which no useful activity could be found. Inhibition of MVAPP decarboxylase may however still be a valid target to control cholesterol biosynthesis. 6-FMVAPP is too prone to be inactivated by phosphatases to be seriously considered for evaluation in vivo. Substitution of phosphates or pyrophosphates by phosphonates or phosphonophosphates has yielded inhibitors of phosphomevalonate kinase, prenyl -transferase and squalene synthetase (Corey & Volante, 1976; Parker et al., 1978; Popj'ak et al., 1978) . By analogy, analogues of that kind for 6-FMVAPP may yield potent inhibitors of MVAPP decarboxylase stable enough to be tested in vivo.
